Alnylam Q3 Beats; Raises 2025 Guidance

Alnylam reported Q3 2025 revenue of $1.249 billion, up from $500.9 million a year earlier, and net income of $251.1 million, delivering a material EPS beat and a swing to profitability. The quarter was driven by Amvuttra, which generated roughly $685 million in sales (about $300 million from ATTR‑CM), with ATTR‑CM revenues about doubling from Q2 and strong uptake across nearly all of its 170 priority health systems. Management raised 2025 revenue guidance to about $3.05 billion on robust Amvuttra launch momentum. Despite the beat, shares fell about 7% after the release following a roughly 105% year‑to‑date gain. Analysts reacted positively — Raymond James raised its price target to $472 (analyst targets range roughly $236–$570) — while observers cautioned that future performance will depend on sustained demand, margin trends and sector competition.